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Lymphoma, cryoglobulinemia, and renal disease
Principal Discussant: C. M. LOCKWOOD
Hammersmith Hospital, London, England
Case presentation
A 50-year-old white male was admitted to New England Medi-
cal Center Hospital (NEMCH) for evaluation of adenopathy and
hypertension.
The patient was in good health until 2 months earlier when he
developed anterior cervical adenopathy and fatigue. Over the 2
months prior to admission he suffered from drenching night
sweats and debilitating arthralgias and lost 9 kg of weight. His
local physician found hypertension (blood pressure, 208/110mm
Hg), hepatosplenomegaly, and diffuse adenopathy, and referred
the patient for admission to NEMCH.
On admission to the hospital, the physical examination re-
vealed the blood pressure to be 195/102 mm Hg. There was non-
ender symmetrical adenopathy (submandibular, posterior cer-
vical, axillary, and supraclavicular nodes) and hepatospleno-
megaly. No hemorrhages, exudates, or other abnormalities were
found on funduscopic examination.
Laboratory findings revealed the following data: hemoglobin,
10.1 g/l00 ml; hematocrit, 29%; white blood cell (WBC) count,
6300/cu mm with 43% polymorphonuclear leukocytes, 53% lym-
phocytes, and 4% monocytes; serum creatinine, 2 mg; blood
urea nitrogen, 39 mg; serum albumin, 4.8 g; total serum protein,
7 g/l00 ml. Results of urinalysis revealed: protein, 3+; urine
sediment, numerous red blood cells (RBC); 4 to 7 WBC and 3 to
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S hyaline casts per high power field (HPF); no RBC casts on
multiple urinalyses; 24-hr urine protein excretion, 3 g. An i.v.
urogram revealed the right kidney to be 14.8 cm long and the left
kidney to be 15.5 cm long. The ureters were not displaced. Addi-
tional serum findings were: total hemolytic complement, 7 U
(normal, 190 to 250 U); Clq, 0 mg (normal, 0.16 to 0.2 mg); C3,
0.48 mg (normal, 0.87 to 2.2 mg); C4, 0.006 mg (normal, 0.15 to
0.54 mg/mI); cold agglutinins, negative; cryoglobulins were pres-
ent in large amounts in the serum but could not be quantified
because of their solubility characteristics. Serum concentrations
of immunoglobulins were: 1gM, 19.6 mg; IgA, 0.31 mg; IgG, 5.7
mg/mI. Protein electrophoresis and immunoelectrophoresis of
serum warmed to 370 C showed an 1gM kappa monoclonal spike
that was almost entirely removed by cryoprecipitation; free kap-
pa light chains were found in the urine. An 1gM kappa mono-
clonal protein was present in the cryoprecipitate along with
traces of IgG and 1gM, however, precise characterization was
not possible; no rheumatoid factor activity was detectable in the
cryoprecipitate. Assays for antinuclear antibody, anti-RNA pro-
tein, and hepatitis B antigen were all negative.
A biopsy of the left axillary lymph node revealed a well-dif-
ferentiated lymphocytic malignant lymphoma. T and B cell mark-
er studies revealed: neutral red <1%; E-rosettes, 41%; surface
markers for IgA, IgD, lgG, and lambda light chains <1%; 1gM,
25%; kappa light chains, 22%. These surface markers on periph-
eral blood lymphocytes exhibit restriction of surface membrane
immunoglobulins to 1gM type kappa, a finding that corresponds
to the monoclonal protein found in the serum. Bone marrow
biopsy revealed nodular and diffuse well-differentiated lympho-
cytic infiltrates.
Hypertension was controlled with small doses of propranolol,
and cyclophosphamide (100 mg daily) and prednisone (80mg dai-
ly) were given. Two large volume (4000 cc) plasmaphereses were
performed on successive days. Four days after the second plas-
mapheresis, the patient noted a marked decrease in arthralgias.
One week later, the serum creatinine concentration was 1.5 mg/
100 ml and the serum cryoglobulin concentration, measured on
two occasions, was normal. Over the next 4 months, cyclophos-
phamide was continued and the prednisone dose was tapered.
Follow-up studies performed at the end of that time period
showed the serum protein electrophoresis to be normal and 1gM
and C3 concentrations had also returned to normal; however, C4
and Clq concentrations and hemolytic complement level re-
mained markedly depressed.
One year after therapy was initiated the patient was working
full time and feeling well. Serum creatinine concentration was
1.1 mg/l00 ml and results of urinalysis revealed 2 to 4 RBC/HPF
and no protein.
Discussion
DR. C. M. LOCKWOOD (Research Fellow, Ham-
mersmith Hospital, London, England): It is a plea-
Lymphoma, cryoglobulinemia, and renal disease 523
sure to be here to discuss the course of this patient
with lymphocytic lymphoma, cryoglobulinemia,
and presumed glomerulonephritis, in whom there
proved to be novel aspects both to his disease and
to the mode of therapy. In this presentation, I want
first to discuss some of the features of cryoglobulin-
emia; second, to report our experience with the use
of plasma exchange in the management of immune
complex nephritis and cryoglobulinemia; and third,
to examine the features of the cryoglobulinemia and
glomerulonephritis in this patient.
Classification of cryoglobulins. The term cryo-
globulin was introduced in 1947 by Lerner, Barn-
um, and Watson to describe a group of serum pro-
teins that showed reversible precipitation in the
cold [1]. Today we know that, apart from cryofi-
brinogen and C-reactive protein-albumin com-
plexes, most cryoproteins are immunoglobulins in
one form or another and that any of the major
classes—IgG, IgA, or 1gM—may take part in cryo-
globulin formation. Cryoglobulins are classified in
the following way: type I is a single monoclonal im-
munoglobulin; type 2 are mixed cryoglobulins, con-
sisting of two or more immunoglobulins, one of
which is monoclonal; type 3 is polyclonal, con-
sisting of one or more polyclonal immunoglobulins
[2].
Isolation of cryo globulins and identification of
diseases associated with cryoglobulinemia. The op-
timal method for cryoglobulin isolation necessitates
use of warm instruments for the collection of blood,
and of prewarmed containers for the initial in-
cubation. After exposure to cold, the serum should
be observed for some time to allow for the emer-
gence of a cryoprecipitate. Monoclonal cryoglobu-
lins may precipitate within 24 hours at 40 C, where-
as mixed cryoglobulins may take as long as 72 hours
to precipitate at this temperature.
In what context do cryoglobulins occur? Rele-
vant to the patient presented today is the presence
of these proteins in hematologic malignancies and
lymphoproliferative disorders. In these disorders,
the monoclonal cryoglobulins are characteristic,
particularly IgG cryoprecipitates with multiple
myeloma, and 1gM cryoprecipitates with Walden-
strom's macroglobulinemia. Cryoglobulins also oc-
cur in association with acute or chronic infections
and collagen vascular diseases; most often these are
mixed cryoglobulins. In 1966, Meltzer et al de-
scribed mixed essential cryoglobulinemia, a syn-
drome consisting of purpura, arthralgia, lymphade-
nopathy, and hepatosplenomegaly associated with
large concentrations of 1gM and IgG cryoprecipi-
tates [3]. This syndrome is of particular importance
because some of the patients develop rapidly pro-
gressive glomerulonephritis (RPGN) as a con-
sequence of the cryoglobulinemia. Cryoglobulins
may also be found in patients who later develop a
myeloproliferative disorder. As a final complicating
matter, it should be remembered that concentra-
tions of cryoglobulins as high as 80 g/m1 have been
described in apparently normal individuals [4].
Physical properties. Although these proteins are
defined by their cold insolubility, certain features
seem to predispose to cold precipitation. Of these, I
think protein concentration is the most important.
The higher the concentration of the cryoprotein, the
higher the temperature at which precipitation oc-
curs. Stated another way, the same protein that pre-
cipitates at high temperature and high concentra-
tion, upon dilution requires a progressively lower
temperature to effect a similar degree of precipi-
tation [1, 3]. This phenomenon applies nicely to our
discussion today of the efficacy of plasma exchange
in reducing the concentration of circulating cryo-
globulins: later I will describe one of our patients
who well illustrates this therapeutic effect.
The optimal pH range for precipitation of cryo-
globulins lies between pH 5.5 and pH 8, and pro-
gressively lower salt concentration produces less
solubility for most cryoglobulins, but not all [3].
The mechanisms of cold precipitability of these
proteins is not entirely explained. Ultracentrifugal
studies indicate that two types of cryoglobulins ex-
ist, with sedimentation coefficients of 19S and 7S
[2]. Various studies suggest that cryoglobulins are
immunoglobulins that are not different from other
immunoglobulins in molecular weight, viscosity,
and diffusion coefficients. Chemical analysis either
by amino acid configuration or N-terminal composi-
tion has also failed to disclose any unique structure
that accounts for cryoprecipitability [5]. Studies of
the chemical forces of intermolecular interactions
that produce precipitation have shown these forces
to be weak, and our best current hypothesis is that
cryoprecipitability results from a variety of non-
covalent interactions such as hydrogen bonding and
hydrophobic forces.
Immunochemical characterization of cryoglobu-
lins. In considering the immunochemical character-
ization of cryoglobulins, Brouet et al have reported
the frequency of various types of cryoglobulins that
occurred in 86 consecutive patients [6]. In Brouet's
series, 50% of the cryoglobulins were polyclonal;
25% were monoclonal (1gM was more frequent than
IgG); and 25% were mixed. In the last group, 19
of 22 cryoglobulins showed a monoclonal 1gM com-
ponent.
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Studies of light chain classes show that approxi-
mately 95% of the 1gM cryoglobulins have light
chains of the kappa type but that this high propor-
tion does not obtain for the IgG cryoglobulins [2, 6].
Studies of the variable region have not been exten-
sive enough to permit understanding of the role it
might play, but some data are available on heavy
chain subclasses: it appears that among IgG cryo-
globulins, IgG3 is the predominant subclass. This
finding may provide insight for our understanding of
relative solubility because this subclass has a much
higher molecular weight than the other subclasses
[7].
I want to mention briefly the characteristics of
cryoglobulins that have rheumatoid factor activi-
ty—that is, those that test positive for rheumatoid
factor. All cryoglobulins that have rheumatoid fac-
tor activity must, of course, be of the mixed variety
because the rheumatoid factor is combined with
IgG. For all instances in which the cryoglobulin ex-
hibits rheumatoid factor activity, the antigen is IgG.
While the noncryoglobulin rheumatoid factors have
a wide spectrum of reactivity, the cryoglobulin
rheumatoid factors have a more restricted spec-
trum, reacting most commonly with IgG 1, 2, and 4
[7-9]. The significance of this particular feature,
however, is not certain.
Cryoglobulins as immune complexes. The evi-
dence that mixed cryoglobulins may behave as im-
mune complexes can be summarized as follows:
First, analytical ultracentrifugation of the isolated
cryoglobulin shows two distinct peaks, a 7S and a
19S [10]; second, many patients with mixed
cryoglobulinemia show activation of the com-
plement system, as evidenced by low levels of com-
plement components [11]; third, immunofluores-
cence of tissue from patients with cryoglobulinemia
complicated by glomerulonephritis or cutaneous
vasculitis show deposits of IgG, 1gM, and occa-
sionally complement [3, 12].
Attempts to identify the antigen responsible for
generation of a cryoglobulin, or to characterize the
antibody specificity of the components of the cryo-
globulin have not been particularly successful. In
one series of patients with poststreptococcal gb-
merulonephritis, the cryoprecipitates were found to
contain specific antigen or specific antibody, but not
both [13]. A search for DNA in the cryoprecipitate
of patients with systemic lupus erythematosus has
shown that only a very small proportion of total
DNA in the serum is contained in the cryoprecipi-
tate, and thus it is unlikely that DNA is involved as
the antigen [14]. In patients with glomerulitis and
vasculitis associated with hepatitis B, however,
cryoprecipitable complexes of hepatitis B antigen,
specific antibody, and 1gM rheumatoid factor have
been isolated. The localization of these proteins in
the glomeruli or in the vessels has suggested an im-
munopathogenetic role for the cryoprecipitates,
representing the best evidence that cryogbobulins
appearing in association with a specific antigen be-
have as immune complexes [13, 15].
Treatment. The therapeutic approach should be
directed toward the condition associated with the
cryoglobulinemia—for example, chemotherapy for
lymphomas. Steroid and immunosuppressive
agents have been effective in the management of
some patients with monoclonal cryoglobulinemia
[16, 17], but these agents are not often effective in
the management of essential mixed cryoglobuline-
mia [3]. Dissociation of the cryoglobulins by reduc-
tion of the immunoglobulin disulphide bridges has
been attempted using penicillamine—which also in-
hibits the formation of 1gM cryoprecipitate—but the
effect is delayed for 2 to 3 weeks after therapy is
begun [18, 19].
Plasmapheresis is the newest approach to therapy
of cryoglobulinemia. We have used plasma ex-
change to effect immediate removal of cryogbobu-
bins in two patients with mixed cryogbobulinemia
whose relevant clinical and laboratory features are
shown in Table 1. All of the work I refer to here was
carried out jointly with Dr. B. Pussell. Our ap-
proach was based on procedures that we developed
for the management of patients with RPON [20, 21].
In such patients we were able to remove patho-
genetic antibody or immune complexes by plasma
exchange and in addition we were able to demon-
strate a significant effect on the splenic component
of reticuloendothelial system (RES) function [22].
In patient 1 (see Table 1), successful removal of the
cryogbobulins by a series of four plasma exchanges
did not alter the clinical course because massive ce-
rebral infarction, found at autopsy, probably oc-
curred before starting plasma exchange. In patient
2, however, it was possible to measure cryoglobulin
concentrations and to test RES function before and
after a series of plasma exchanges; strikingly, im-
paired RES function improved after plasma ex-
change despite the continuing presence of circulat-
ing cryogbobulins, albeit at a lower level. Figure 1
shows the quantitative heat-damaged red cell scans
before and after four plasma exchanges. Another
feature of interest in this patient—and the one I al-
luded to earlier—was the alteration in the temper-
ature required to bring about cryoprecipitation after
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Table 1. Clinical and laboratory data for two patients with mixed cryoglobulinemia who underwent plasma exchange for removal of
cryoglobulins at Hammersmith Hospital.
Clinical data Laboratory data Response to therapy
Patient /
Male, age 54 Purpura and arthralgia, 4 years
Fluctuating neurological signs
Glomerulonephritis, 9 days
Coma at presentation
Serum studies
C3, 60%; C4, 5%
Rheumatoid factor positive
IgM/IgG cryoglobulin (type 2)
Monoclonal 1gM component
Received 4 daily 4-liter plasma exchanges
but neurological status deteriorated; death
occurred 5 days afterlast exchange.
Autopsy showed massive cerebral infarction
and mesangiocapillary glomerulonephritis
with necrotizing vasculitis. Immuno-
fluorescence of kidney specimen showed de-
posits of 1gM, IgG, and C3 in capillary
loops.
Patient 2
Female, age 75 Purpura, 9 months
Distal neuropathy and para-
esthesia, 7 months
Vasculitic skin lesions with exten-
sive ulceration, 6 months
Disease unresponsive to predni-
sone, 50 mg/day and azathioprine,
2 mg/kg/day.
Serum studies
C3, 50%; C4, 8%
Rheumatoid factor positive
IgM/IgG cryoglobulin (type 2)
Monoclonal 1gM component
with kappa light chains.
Skin biopsy
Immunofluorescent examina-
tion showed deposits of IgG
and 1gM
Received 104-liter plasma exchanges and
cryoglobulin levels fell (see Fig. 2). Cutane-
ous lesions healed rapidly. At follow-up 6
months later, C3 was 98% C4 was 62%,
cryoglobulins were 1.4 mg/mI, and disease
was in clinical remission.
a Complement values are expressed as % of normal human serum.
the concentration of cryoglobulins was lowered; the of this Forum, several interesting features emerge.
temperature at which cryoprecipitation occurred The abnormal M band was almost entirely removed
was 35° C before, and 29° C after exchange (Fig. 2). by cryoprecipitation and did not contain rheuma-
Particular features of the patient presented toid factor activity. Precise characterization of the
today. In considering the patient who is the subject cryoglobulin could not be carried out, however, and
Fig. 1. Distribution of 99Tc label/ed heat-damaged red blood cells in a patient with mixed cryoglobulinemia (patient 2, Table 1) before
(left) and after (right) 4 plasma exchanges performed over 4 days. The splenic uptake was 23% before exchange and 47% after: normal
splenic uptake is from 50 to 60% of heat-damaged cells 1 hour after injection.
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IgA and IgG were present either as contaminants of
a monoclonal 1gM cryoprecipitate or as trace com-
ponents of a "mixed" cryoglobulin.
There is some difficulty in attempting to under-
stand the combination of this patient's serologic
findings and the renal involvement. The occurrence
of glomerulonephritis in association with a cryo-
globulin composed solely of a monoclonal immuno-
globulin is extremely rare. There is no doubt, of
course, that the complement system was activated,
as shown clearly by the low levels of complement
components, particularly the greatly depressed lev-
els of Cl, C2, and C4, and the lesser depression of
C3. Such findings are especially characteristic of
mixed cryoglobulinemia. Complement activation,
however, by a monoclonal cryoglobulin alone has
been described [23]. Presumably, activation occurs
because aggregation of 1gM at low temperature can
be followed by fixation of Clq and subsequent acti-
vation of the rest of the complement system at
370 C. It is likely that the greater the concentration
of the monoclonal protein, the easier the formation
of the aggregate and the subsequent activation of
the complement system. The type 2 cryglobulin
would, however, be much more likely to be in-
volved, and it is unfortunate that a renal biopsy was
not performed: Immunofluorescent examination
might have allowed comparison of the components
of the cryoglobulin isolated from the serum with
that deposited in the glomerulus. Histologic charac-
terization also would have confirmed the diagnosis
and allowed assessment of the degree of renal injury
due possibly to the preceding hypertension. In view
of findings such as the elevated serum creatinine
concentration, the proteinuria, the red blood cells in
the urine sediment, the presence of cryoglobulins,
40 and the activation of the complement system, it
seems likely that the renal lesion was glomerulone-
38 phritis and not another cause such as myeloma kid-
36 ney or amyloidosis.
The persistence of C4 deficiency after restoration
34 of normal levels of C3 in this patient is noteworthy
320 because primary deficiency of complement com-ponents can be associated with the development of
30 immune complex disease [24]. One explanation for
renal involvement in these complement deficiency
28
states is that removal of immune complexes by sol-
26 ubilization requires a functionally intact com-
plement pathway [25]. As evidence in support of
this hypothesis, studies now in progress in our labo-
ratory by Drs. Pussell, Bartolotti, Peters, and my-
self show that many patients with immune complex
disease have a defect in their ability to solubilize
immune complexes in vitro and that this defect can
be corrected by plasma exchange. Future investiga-
tion may shed more light on the nature of the C4
deficiency in this patient.
The patient responded to a therapeutic regimen
that included two 4-liter plasma exchanges, cyclo-
phosphamide, and prednisone by prompt loss of
symptoms, sustained improvement in renal func-
tion, and virtual disappearance of the cryoglobu-
lins. Four months later the monoclonal spike was
still absent from the serum and at that time 1gM lev-
els were normal. Such control of immunoglobulin
synthesis is remarkable. In the recent studies from
our laboratory that I referred to before, however,
we have evidence that plasma exchange plays a role
in this control process. We have examined the ef-
fect of plasma exchange, cyclophosphamide, and
prednisone on antiglomerular basement membrane
(anti-GBM) antibody synthesis in patients with anti-
GBM disease; in a group of patients matched for the
severity of their disease, initial antibody titer, and
duration of immunosuppression, we have shown
that the half-life survival of circulating antibody was
considerably shorter in those patients who received
the most plasma exchanges.
Finally, I would like to return to the effect of pro-
tein concentration on cryoprecipitability. In the pa-
tient I described before, we showed that lowering
the concentration of protein had a profound effect
on the temperature at which precipitation occurred.
It seems possible that the varying concentrations of
protein found along the glomerulus and tubule may
predispose toward cryoprotein precipitation. As in
the patient discussed today, lowering the cryopro-
tein concentration abruptly by plasma exchange
may lead to cessation of such precipitation. This hy-
pothesis argues for the early use of plasma ex-
change in the management of patients with cryo-
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Fig. 2. Cryoprotein concentration and temperature ofprecipi-
tation of serial blood samples from a patient with mixed crvo-
globulinemia (patient 2, Table 1) during 10 plasma exchanges
(denoted by arrows.
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globulinemia and evidence of progressive tissue
damage, particularly those with progressive renal
insufficiency.
Questions and Answers
DR. J. T. HARRINGTON: Dr. Agnello, would you
care to comment on the quantitation and character-
ization of the cryoprecipitate in this patient?
DR. VINCENT AGNELLO (Chief, Rheumatology
and Clinical Immunology, NEMCH): Unfortu-
nately, the solubility properties of the cryoprecipi-
tate were such that a precise quantitation and char-
acterization was not possible; however, from the
initial observations of the cryoprecipitate before
washing, it was clear that large amounts of the
cryoprecipitate were present. An 1gM kappa mono-
clonal protein that did not have rheumatoid factor
activity was present in the serum and cryoprecipi-
tate. Little more can be said about the composition
of the cryoprecipitate. The complement studies
may, however, provide some clues as to the sero-
logical events that occurred in this patient. The
changes in complement component profile during
the acute and later phases suggest that during the
acute phase there was activation of C3. It is con-
ceivable that 1gM kappa protein when present in
very high concentrations may activate complement
and produce the same sort of damage as found with
immune complexes. Verroust et al have presented
evidence in support of this mechanism [26]. Studies
have not been done on the 1gM kappa protein in this
patient to determine its complement fixing activity,
but such studies might resolve some of these ques-
tions.
Another possibility is that the monoclonal protein
reacted with an antigen to form immune complexes
during the acute phase; with the subsequent dis-
appearance of the monoclonal protein, the immune
complex formation ended. This hypothesis would
explain the transient nature of what probably was a
glomerulonephritic process.
DR. J. J. COHEN: I am not sure I understand. Do
you mean there was an 1gM monoclonal protein in
the cryoprecipitate that was capable of combining
with an antigen in the circulation?
DR. V. AGNELLO: Yes. I am raising that as an
alternative hypothesis. The 1gM kappa protein may
be an antibody to an uncharacterized antigen and
may form immune complexes that precipitate in the
cold. This, in fact, has been demonstrated by Day et
al in a patient whose course was very similar to that
of this patient [27].
DR. C. M. LOCKWOOD: Other data have sug-
gested a role for an antigen in that it has been shown
that lipoprotein determinants can stimulate binding
of Cl to monoclonal 1gM and so activate the com-
plement system [23].
DR. V. AGNELLO: I would not apply that hypoth-
esis here. I think the glomerulonephritis is related to
the underlying B-cell leukemia. The malignant B-
cell is probably producing the monoclonal protein,
as can be demonstrated in many such patients. In
some instances, as in Day's patient, immune com-
plexes involving the monoclonal antibody can be
demonstrated. In that patient, the immune com-
plexes consisted of an 1gM kappa antibody directed
to a lymphocyte antigen. Incidentally, the com-
plement profile was very similar to that in the pa-
tient presented here.
DR. J. P. KASSIRER: That is an exciting and inter-
esting integration of the pathophysiology in this pa-
tient. I take it that you could have been more con-
fident of this hypothesis if you had been able to
identify a monoclonal protein and complement
components in the glomeruli during the period in
which the glomerular disease was active.
DR. C. M. LOCKWOOD: Yes, it is a great draw-
back not to have the results of a renal biopsy, so we
can only speculate.
DR. V. AGNELLO: But even without the biopsy
information, I do not think there is evidence for es-
pecially nephrotoxic types of immune complexes in
this patient; rather a transient high concentration of
the 1gM kappa antibody, as suggested, may have
been involved in the renal process. The marked de-
pression of complement in this patient is, however,
a little misleading. The first and fourth components
of complement were still undetectable following the
disappearance of the monoclonal protein. It is likely
that this patient had a lymphoproliferative disease
with marked depression of Cl and C4 and probably
Cl esterase inhibitor as well, similar to the patients
reported by several centers [27—31]. This patient did
not have angioedema hut about one-half of such pa-
tients do because of the activation of the com-
plement system.
After the monoclonal protein disappeared from
the serum, evidence of the basic leukemic process
was still apparent, but there was no ongoing process
in the kidney. These results can probably be attrib-
uted principally to the treatment of the underlying
condition. I think, however, you can make a case
for some very beneficial effects of plasmapheresis:
There were very high concentrations of cryopre-
cipitate, there was activation of C3, and a mild to
moderate disturbance of renal function.
DR. C. M. LOCKWOOD: Yes, I agree with those
comments. Concentration of cryoglobulin is very
important in that there is reason to believe that
lowering the concentration may avert the cryopre-
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cipitation. It isn't necessary to get rid of the cryo-
globulin entirely, but perhaps by lowering its con-
centration and thus changing the temperature at
which cryoprecipitation occurs, it might be possible
to protect target organs.
DR. DAVID J. SALANT (University Hospital, Bos-
ton): First, in the patients whom you have studied
with circulating immune complexes, what evidence
is there of immune complex disease? Did they have
positive immunofluore scent findings for IgG and
complement? Second, one can understand that the
removal of circulating immune complexes, which
are choking the RES, by plasmapheresis allows the
heat-damaged red blood cells to be taken up by the
system. I am not sure that I understand the discrep-
ancy between your test of RES function improving
with steroid therapy and the experimental data of
Haakenstad, Case, and Mannik, which showed that
steroids inhibited the RES clearance of circulating
immune complexes [32].
DR. C. M. LOCKWOOD: In answer to your first
question, we have more data available about the im-
mune complex status of our patients with RPGN.
Of the sera that we examined, we found that 10 out
of 18 patients had Clq binding material initially, and
4 patients, 2 of whom weren't in that 10, had cryo-
globulins. We had 12 biopsies available for immuno-
fluorescent studies; 9 of those 12 showed granular
deposits and 3 did not. One of those patients did not
have granular deposits but had circulating immune
complexes by our assay.
In answer to your second question, we do not
know the effect of steroids on splenic function as
judged by our tests in normal subjects; nor do we
have sufficient data to analyze the effects of steroids
in the short term—hours or days—in patients with
immune complex disease and impaired splenic func-
tion. In some patients who have putative immune
complex disease relatively long-term studies over
weeks to months have shown that splenic function
reverts to normal. Final analysis of the action of ste-
roids on splenic function and immune complex
clearance will probably require study in the experi-
mental animal.
DR. D. SALANT: Have you looked for the factor
or factors that impair RES function? Have you done
sucrose gradient studies on the size of complexes?
DR. C. M. LocKwooD: We have taken the stored
plasma of some of our patients in an effort to isolate
Clq binding material on the sucrose gradient, but so
far we have not been particularly successful.
DR. V. AGNELLO: The technical advances that
have been made in the performance of plasmapher-
esis render small plasma exchange a maneuver of
little risk. As in the patient under discussion, it
wasn't absolutely clear that the immune complexes
were playing a major role in the pathogenesis of gb-
merulonephritis, but the risk of waiting I to 2 weeks
for cyclophosphamide and corticosteroids to have
an effect was relatively great compared with the
small risk of plasmapheresis. Have you found any
major complications in performing multiple plasma
exchanges?
DR. C. M. LocKwooD: Infection is the major po-
tential complication. We are currently analyzing the
incidence of infection in all of our patients who have
received immunosuppressive agents—that is, those
who have been given high-dose steroids and cyto-
toxic drugs—and included with these are patients
who have had plasmapheresis. It is my feeling that
plasma exchange does not carry any increased risk.
A further factor to be considered is the role that
splenic blockade may have in enhancing suscepti-
bility to infection.
DR. J. J. COHEN: You have discussed the risks of
the procedure and in focusing on the possible ben-
efits you indicated that there are suggestions that
cyclophosphamide or immunosuppressive agents
either alone or coupled with steroids may be ef-
fective in some diseases. Whether the plasma ex-
change procedure adds anything to the ef-
fectiveness of the treatment is at issue. Until a truly
controlled study to consider potential benefits is
conducted, I'm afraid this will be a worrisome is-
sue. Is there a plan to launch such a study?
DR. C. M. LocKWooD: We are currently con-
ducting a randomized trial of patients who have se-
vere glomerulonephritis and who fall into the puta-
tive immune complex category. One group receives
prednisone and cyclophosphamide, and the other
group receives prednisone, cyclophosphamide, and
plasma exchange.
DR. J. J. COHEN: Whether or not there is any ben-
efit from plasma exchange, the trial you are con-
ducting should provide a wonderful opportunity to
perform kinetic studies of the reappearance of the
materials removed by the plasma exchange.
DR. C. M. LOCKWOOD: At the moment we have
little data on changes of levels of immune com-
plexes but we do have some information on the anti-
body-mediated diseases such as anti-GBM disease.
We have studied how the anti-GBM antibody re-
turns compared with the normal IgG. Our data
show that there is very vigorous synthesis at least in
some patients. We believe that the rapidity of syn-
thesis may be important, in that there may be a
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much more dynamic equilibrium between antibody
fixed to the glomerular basement membrane and
antibody in the circulation.
DR. J. P. KASSIRER: Dr. Berkman, can you tell us
the cost of a single 4-liter plasmapheresis in this
country?
DR. EUGENE BERKMAN (Chief, Blood Bank,
NEMCH): The Blue Cross, Blue Shield billing would
be approximately $1,800. The direct cost of albumin
and disposable out-of-pocket expense to the hospi-
tal would be close to $800. The albumin is the major
expense at $80/vial. One procedure usually requires
8 vials.
DR. J. T. HARRINGTON: Given the cost and dif-
fering views about when plasmapheresis is in-
dicated in immune complex disease, do you have
any "absolute" criteria for plasmapheresis? For in-
stance, do you use it in all patients with anti-GBM
disease?
DR. M. LocKwooD: Yes, we do, provided there
is some residual renal function. We feel that both
the recent data from our own and other's experi-
ence indicate the disease may have a very different
outcome from the usually expected poor prognosis.
We perform plasmapheresis on a daily basis until a
satisfactory change in the serum creatinine concen-
tration is evident. In our experience, the renal func-
tion in patients with a serum creatinine concentra-
tion below the level of 8 mg/100 ml has improved in
every instance except one. By contrast, we have
never been able to restore stable renal function in
patients presenting with anuria or prolonged oh-
guria. In these patients, one indication for plasma
exchange would be lung hemorrhage and our expe-
rience here is that this complication was controlled
in 25 of 26 patients in whom it was a feature.
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The editors should like to expand the scope of these exercises by encouraging active partici-
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cal Center Hospital, 171 Harrison Avenue, Boston, Massachusetts 02111. To be eligible for
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